The ALKBH3 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ALKBH3 gene, generated from the human HAP1 cell line. This product provides a loss-of-function model for investigating ALKBH3-mediated nucleic acid repair and its downstream biological effects. The polyclonal format ensures a heterogeneous pool of edited alleles, enabling robust population-level studies without clonal selection artifacts. As a ready-to-use knockout tool, it is optimized for applications requiring efficient disruption of the ALKBH3 locus, including functional genomics, drug response profiling, and signal transduction analyses.
The parental HAP1 cell line is a near-haploid chronic myeloid leukemia model derived from KBM-7 cells, characterized by an adherent, fibroblast-like morphology and the absence of one copy of most chromosomes. This near-haploid karyotype facilitates efficient CRISPR/Cas9-mediated gene disruption, as targeting a single allele is often sufficient to generate a functional knockout. HAP1 cells retain key DNA damage response and apoptosis pathways, making them a versatile platform for studying repair enzymes and stress signaling. Their well-defined genetic background and ease of manipulation support high-throughput and mechanistic experiments in cancer biology.
ALKBH3 functions as an iron(II)- and 2-oxoglutarate-dependent dioxygenase that catalyzes oxidative demethylation of N1-methyladenine in mRNA and tRNA, as well as N3-methylcytosine in DNA and RNA. By reversing alkylation damage, it preserves translational fidelity and prevents apoptosis under genotoxic stress. ALKBH3 is transcriptionally regulated by TP53 and HIF1A and is activated downstream of alkylating agents such as methyl methanesulfonate and N-methyl-N??-nitro-N-nitrosoguanidine. It interacts with PCNA and ASCC3, linking it to DNA replication and repair complexes. Downstream, ALKBH3 modulates BCL2 family protein expression and translation fidelity factors, ultimately influencing cell survival. Pathway components intersecting with ALKBH3 include ALKBH2, MGMT, APE1, POLB, LIG3, ATM, ATR, and p53, positioning it within the broader alkylation damage repair and base excision repair networks.
In the HAP1 background, ALKBH3 disruption provides a physiologically relevant context for dissecting its role in alkylation damage repair and RNA demethylation. The near-haploid system magnifies the impact of gene loss, revealing phenotypes that might be buffered in diploid models. This knockout population enables researchers to assess how ALKBH3 deficiency affects sensitivity to alkylating chemotherapeutics, activation of ATM/ATR-dependent DNA damage checkpoints, and crosstalk with p53-mediated apoptosis. Given ALKBH3’s overexpression in lung adenocarcinoma, pancreatic ductal adenocarcinoma, and prostate cancer, the model serves as a valuable tool for identifying synthetic lethal interactions and mechanisms of chemoresistance.
Typical applications include Western blotting and RT-qPCR for knockout verification, RNA-seq to characterize transcriptome-wide methylation changes, and ChIP-qPCR and immunofluorescence to quantify DNA damage foci marked by ??H2AX. Functional assays such as flow cytometry for apoptosis, phospho-ATM/ATR analysis, and drug sensitivity or colony formation assays are routinely employed to evaluate stress responses. Comet assays further measure DNA strand breaks, enabling comprehensive characterization of repair kinetics. These polyclonal ALKBH3 knockout cells are suitable for chemical mutagenesis screens and synthetic lethality studies aimed at identifying novel therapeutic targets. For additional technical specifications and support, please contact Ascent Research.
